Drugs / PBCAR20A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04030195 | Mar 2020 → Jun 2021 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Precision BioSciences, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-11-12 | Precision BioSciences, Inc. | Regulatory Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial precisionbiosciences.com ↗
Received acceptance from US Food and Drug Administration ( FDA ) of investigational new drug (IND) application for second and wholly-owned allogeneic CAR T therapy candidate PBCAR20A, targeting CD20. |
| 2019-09-16 | Precision BioSciences, Inc. | Regulatory Precision BioSciences Announces FDA Clearance of the IND for PBCAR20A, a CD20 Targeting Genome Edited Allogeneic CAR T Therapy precisionbiosciences.com ↗
today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for PBCAR20A |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-04-07 | Precision BioSciences, Inc. | Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL precisionbiosciences.com ↗ |
| 2019-11-12 | Precision BioSciences, Inc. | Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial precisionbiosciences.com ↗ |
| 2019-09-16 | Precision BioSciences, Inc. | Precision BioSciences Announces FDA Clearance of the IND for PBCAR20A, a CD20 Targeting Genome Edited Allogeneic CAR T Therapy precisionbiosciences.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBCAR20A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04030195 ↗ |
| Modality | Cell therapy | “allogeneic anti-cluster of differentiation (CD20) CAR T Cells” NCT04030195 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion of PBCAR20A” NCT04030195 ↗ |